GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin.

Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide

was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are

presumed to increase lipolysis (fat loss). The DAC (Drug Affinity Complex) portion increases the half-life

by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed

when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).